CM – Pfizer provides abrocitinib, an update to the regulatory schedule for XELJANZ

0

Similar title :
Pfizer Updates US FDA Review of Abrocitinib and XELJANZ
Pfizer Announces Update on US FDA Review of Abrocitinib and XELJANZ® Filings
Pfizer offers abrocitinib, government XELJANZ timeline update

Keywords:

Pfizer,Tofacitinib,Food and Drug Administration,Atopic dermatitis,Prescription Drug User Fee Act,Janus kinase inhibitor,Pfizer, Tofacitinib, Food and Drug Administration, Atopic dermatitis, Prescription Drug User Fee Act, Janus kinase inhibitor,,,,

Donnez votre avis et abonnez-vous pour plus d’infos

[gs-fb-comments]

Vidéo du jour: